Frailty and Cancer: Current Perspectives on Assessment and Monitoring
DOI: https://doi.org/10.2147/CIA.S365494
IF: 3.829
2023-03-29
Clinical Interventions in Aging
Abstract:Valentin Goede Department of Oncogeriatrics, Center of Geriatric Medicine, St. Marien-Hospital, Cologne, Germany Correspondence: Valentin Goede, Department of Oncogeriatrics, Center of Geriatric Medicine, St. Marien-Hospital, Kunibertskloster 11-13, Cologne, 50668, Germany, Tel +49 221 1629 2311, Fax +49 221 1629 2306, Email Frailty, an age-related condition of increased vulnerability to acute endogenous or exogenous stressors, is a key barrier to successful treatment of cancer in older people. In this group of patients, assessment of frailty is required before starting a new treatment. According to guidelines, the gold standard to assess frailty in older adults with cancer is geriatric screening followed by geriatric assessment (GA) across essential GA-domains (social status, physical function, nutrition, cognition, emotion, co-morbidity, polypharmacy). GA enables tailoring of both oncological therapy and non-oncological interventions to the patient's vulnerabilities. Large clinical trials recently have demonstrated that the feasibility and tolerability of systemic cancer treatment in older patients are significantly improved by such GA-guided management. Indications and optimal tools for frailty monitoring during the course of cancer treatment have not yet been defined in greater detail. New technologies such as wearable sensors or apps offer promising new opportunities to further develop frailty monitoring. This review describes the current standards and perspectives for the assessment and monitoring of frailty in elderly patients with cancer. Keywords: cancer, frailty, geriatric screening, geriatric assessment Every year, 20 million new cancer cases occur worldwide. 1 Incidence rates are low in younger people, but show a steep increase in older adults. 2 In the United States, for example, 3 the incidence in people up to the age of 50 years is less than 500 per 100,000 inhabitants a year. For those over 70 years, however, it is four times higher. Approximately 30% of US patients newly diagnosed with cancer are 65 to 74 years old. Another 25% are 75 years or older. Comparable incidence rates across age groups have been reported for other regions and countries. 2 Unlike younger patients with cancer, vulnerable older subjects are more susceptible to unfavorable health events and medical complications during the clinical course. "Frailty" is an established term to describe aging-associated vulnerability, 4–7 and it has been recognized as a main obstacle of cancer therapy in patients of advanced age. 8,9 With frailty, longer lasting therapeutic success is more difficult to achieve. For example, frailty increases the risk of chemotherapy intolerance and of poorer treatment response. 10,11 Patients with frailty undergoing cancer surgery have an increased likelihood of post-operative complications. 5,12 Advanced frailty may also pose competing risks of morbidity and mortality independent of cancer and its treatment. The prevalence of frailty in older adults with cancer is around 40–50% with a wide range from 5% to 90% depending on the patient population and the method used to assess frailty. 8,13 Over the past two decades, huge efforts have been made in order to optimize the detection and quantification of frailty in such patients. The basic underlying idea was to determine a patient's individual degree of frailty at baseline (ie, before the start of cancer therapy) and to use this information to adjust the oncological treatment. 14 This includes the decision whether the patient should receive tumor therapy or not as well as the choice of the most adequate treatment modality and regimen (eg, standard versus gentler therapy). 15 The principle of using information from a frailty evaluation to therapeutically target this condition with suitable interventions has been established in geriatric medicine for a long time but just recently adopted to the oncological context. 16 International and national medical societies (eg, International Society of Geriatric Oncology [SIOG], American Society of Clinical Oncology [ASCO]) have developed detailed recommendations for the assessment of frailty in older adults prior to the initiation of cancer therapy. 17–19 There is a growing understanding that frailty in older patients with cancer is not a static biomarker that just needs to be recorded at a single point in time to make final treatment decisions. 20,21 Instead, frailty in such individuals is subject to dynamic changes throughout a patient's remaining lifespan. This raises the question whether and for what specific purposes frailty should be recorded repeatedly during cancer therapy. Compared to the amount of guidance that is available for the initial frailty assessment in old -Abstract Truncated-
geriatrics & gerontology,gerontology